A classifier driven approach to find biomarkers for affective disorders from transcription profiles in blood
Journal Title: Advances in Precision Medicine - Year 2016, Vol 1, Issue 1
Abstract
Gene expression profiles in blood are increasingly being used to identify biomarkers for different affective disorders. We have selected a set of 29 genes to generate expression profiles for healthy control subjects as well as for patients diagnosed with acute post-traumatic stress disorder (PTSD) and with borderline personality disorder (BPD). Measurements were performed by quantitative polymerase chain reaction (qPCR). Using the actual data in an anonymous form we constructed a series of artificial data sets with known gene expression profiles. These sets were used to test 14 classification algorithms and feature selection methods for their ability to identify the correct expression patterns. Application of the three most effective algorithms to the actual expression data showed that control subjects can be distinguished from BPD patients based on differential expression levels of the gene transcripts Gi2, GR and MAPK14, targets that may have links to stress related diseases. Controls can also be distinguished from acute PTSD patients by differential expression levels of the transcripts for ERK2 and RGS2 that are known to be associated with mood disorders and social anxiety. We conclude that it is possible to identify informative transcription profiles in blood samples from individuals with affective disorders.
Authors and Affiliations
Wiktor Mazin, Joseph A. Tamm, Irina A. Antonijevic, Aicha Abdourahman, Munish Das,Roman Artymyshyn, Birgitte Søgaard, Mary Walker, Danka Savic, Gordana Matic, Svetozar Damjanović, Ulrik Gether, Thomas Werge, Lars V. Kessing, Henrik Ullum, Eva Haastrup, Eric Vermetten, Paul Markovitz, Erik Mosekilde and Christophe P. G. Gerald
Keywords
Related Articles
- EP ID EP679278
- DOI -
- Views 143
- Downloads 0
Collaboration for success: the value of strategic collaborations for precision medicine and biomarker discovery
Precision medicine aims to provide the precise treatment for the patient with the right dose at the right point of time. Biomarkers (BM) are vital for the identification of patients who would benefit the most from indivi...
Genomics Vault: A framework for precision medicine data management
A mixture of fumaric acid esters (FAEs) is approved for the oral therapy of psoriasis. However, for a long time the active ingredient of this mixture was unknown. We reviewed the in vitro data available for the different...
Success factors in drug discovery and development
The article aimed to give a personal perspective on drug discovery and development. The author has worked both in Big Pharma as a scientist and manager and more recently also in start-up biotech companies. Drug companies...
Reproducibility of preclinical data: one man's poison is another man's meat
Limited reproducibility of preclinical data is increasingly discussed in the literature. Failure of drug development programs due to lack of clinical efficacy is also of growing concern. The two phenomena may share an im...
Strategy to achieve biomarker-driven immunosuppression after solid organ transplantation by an academic-industry partnership within the European BIO-DrIM consortium
Solid organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure as it improves both quality of life and survival. Despite the progress in short-term graft survival, that is closely asso...